Heather Raymon's most recent trade in Artiva Biotherapeutics Inc was a trade of 46,000 Common Stock done . Disclosure was reported to the exchange on Feb. 15, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Artiva Biotherapeutics Inc | Heather Raymon | SVP, Research and Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2026 | 46,000 | 152,844 | - | 0 | Common Stock | |
| Artiva Biotherapeutics Inc | Heather Raymon | SVP, Research and Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.00 per share. | 15 Feb 2026 | 1,521 | 151,323 | - | 4 | 6,084 | Common Stock |
| Artiva Biotherapeutics Inc | Heather Raymon | SVP, Research and Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Dec 2025 | 67,253 | 106,844 | - | 0 | Common Stock | |
| Artiva Biotherapeutics Inc | Heather Raymon | SVP, Research and Development | Sale or transfer of securities back to the company at price $ 0.00 per share. | 12 Dec 2025 | 18,239 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Artiva Biotherapeutics Inc | Heather Raymon | SVP, Research and Development | Sale or transfer of securities back to the company at price $ 0.00 per share. | 12 Dec 2025 | 14,819 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Artiva Biotherapeutics Inc | Heather Raymon | SVP, Research and Development | Sale or transfer of securities back to the company at price $ 0.00 per share. | 12 Dec 2025 | 12,539 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Artiva Biotherapeutics Inc | Heather Raymon | SVP, Research and Development | Sale or transfer of securities back to the company at price $ 0.00 per share. | 12 Dec 2025 | 11,399 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Artiva Biotherapeutics Inc | Heather Raymon | SVP, Research and Development | Sale or transfer of securities back to the company at price $ 0.00 per share. | 12 Dec 2025 | 10,259 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Artiva Biotherapeutics Inc | Heather Raymon | SVP, Research and Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.25 per share. | 15 Nov 2025 | 1,375 | 39,591 | - | 3.3 | 4,469 | Common Stock |
| Artiva Biotherapeutics Inc | Heather Raymon | SVP, Research and Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.75 per share. | 15 May 2025 | 1,639 | 40,966 | - | 2.7 | 4,507 | Common Stock |
| Artiva Biotherapeutics Inc | Heather Raymon | SVP, Research and Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.13 per share. | 15 May 2025 | 745 | 42,605 | - | 2.1 | 1,587 | Common Stock |
| Artiva Biotherapeutics Inc | Heather Raymon | SVP, Research and Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2025 | 33,350 | 43,350 | - | 0 | Common Stock | |
| Artiva Biotherapeutics Inc | Heather Raymon | SVP, Research and Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Sep 2024 | 10,000 | 10,000 | - | 0 | Common Stock |